Anti-thrombotic Monotherapy With the HeartMate 3 LVAS
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain a single-center safety and feasibility data on
patients managed with a single anti-thrombotic therapy and the incidence of thrombotic
adverse events associated with HeartMate 3 LVAS therapy.